FI116659B - Användning av föreningar vid framställning av läkemedel för behandling av multipel skleros (MS) och andra myelinminskningstillstånd - Google Patents

Användning av föreningar vid framställning av läkemedel för behandling av multipel skleros (MS) och andra myelinminskningstillstånd Download PDF

Info

Publication number
FI116659B
FI116659B FI971290A FI971290A FI116659B FI 116659 B FI116659 B FI 116659B FI 971290 A FI971290 A FI 971290A FI 971290 A FI971290 A FI 971290A FI 116659 B FI116659 B FI 116659B
Authority
FI
Finland
Prior art keywords
lofepramine
phenylalanine
antidepressant
use according
treatment
Prior art date
Application number
FI971290A
Other languages
English (en)
Finnish (fi)
Other versions
FI971290A (sv
FI971290A0 (sv
Inventor
Cari Loder
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Publication of FI971290A0 publication Critical patent/FI971290A0/sv
Publication of FI971290A publication Critical patent/FI971290A/sv
Application granted granted Critical
Publication of FI116659B publication Critical patent/FI116659B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
  • Fodder In General (AREA)

Claims (13)

1. Användning av ett tricykliskt antidepres-sivt ämne eller en monoaminoxidasinhibitor tillsammans med en neurotransmitterinducerande förening, varvid 5 nämnda inducerande förening är en aminosyra, vid fram-ställning av ett läkemedel för behandling av multipel skleros eller andra myelinminskningstillständ, varvid de specifikt nämnda ämnena är framställda för att gi-vas separat eller i en passligt kombinerad form, ute-10 lämnande användningen av imipramin med tryptofan och karbidopa.
2. Användning av ett tricykliskt eller tetra-cykliskt antidepressivt ämne, en serotonin äterupptag-ningsinhibitor, eller en monoaminoxidasinhibitor till- 15 sammans med en neurotransmitterinducerande eller pre-kursor förening, varvid nämnda förening är en aminosyra, vid framställning av ett läkemedel för behandling eller prevention av multipel skleros eller andra mye-linminskningstillständ, varvid de specifikt nämnda 20 ämnena är framställda för att givas separat eller i en passligt kombinerad form, utelämnande användningen av imipramin med tryptofan och karbidopa.
: 3. Användning enligt patentkrav 1, väri den : · inducerande föreningen är L-fenylalanin, tyrosin eller , : 25 tryptofan.
4. Användning enligt patentkrav 1, väri det antidepressiva ämnet är lofepramin.
• · · ‘ 5. Användning enligt patentkrav 1, 3 eller 4, väri det antidepressiva ämnet eller monoaminoxidasin-> 3 0 hibitorn och aminosyran doseras dagligen tillsammans, vilken följs av en daglig tilläggsdos av aminosyra.
6. Användning enligt patentkrav 1, 3, 4 eller , 5 i kombination med användning av vitamin Bi2 .
7. En kombination av ett tricykliskt antide-35 pressivt ämne eller en monoaminoxidasinhibitor till- sammans med en aminosyraneurotransmitterinducerande 116659
8. Användning enligt patentkrav 2, väri det antidepressiva ämnet är lofepramin.
9. Användning enligt patentkrav 1 eller 3, 4 eller 5, väri bäde L-fenylalanin eller tyrosin och L- 5 tryptofan används tillsammans med det antidepressiva ämnet.
10. Användning enligt patentkrav 1 eller nä-got av patentkraven 3-6 kompletterad med användning av vitamin Bi2, säsom t.ex. cyanokobalamin eller hyd- 10 roxikobalamin.
11. Användning enligt patentkrav 1 eller nä-got av patentkraven 3-6, vilken innefattar en daglig dos, vilken är 10 - 220 mg lofepramin och 100 mg - 5 g L-fenylalanin, valbart kompletterad med vitamin Bi2- 15 injektioner.
12. Användning enligt patentkrav 1 eller nä- got av patentkraven 3-6, vilken innefattar en daglig dos, vilken är 70 - 210 mg lofepramin och 500 mg - 3000 mg L-fenylalanin, valbart kompletterad med vita- 20 min Bi2-injektioner.
13. En enhetsdosform, vilken innefattar lofe- ,i pramin (25 - 100 mg) och L-fenylalanin (400 - 600 mg) . t *
FI971290A 1994-10-05 1997-03-26 Användning av föreningar vid framställning av läkemedel för behandling av multipel skleros (MS) och andra myelinminskningstillstånd FI116659B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GB9420116 1994-10-05
GB9502361 1995-02-07
GB9508482 1995-04-26
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (3)

Publication Number Publication Date
FI971290A0 FI971290A0 (sv) 1997-03-26
FI971290A FI971290A (sv) 1997-06-02
FI116659B true FI116659B (sv) 2006-01-31

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971290A FI116659B (sv) 1994-10-05 1997-03-26 Användning av föreningar vid framställning av läkemedel för behandling av multipel skleros (MS) och andra myelinminskningstillstånd

Country Status (19)

Country Link
US (2) US6096737A (sv)
EP (1) EP0784476B1 (sv)
JP (1) JPH10508583A (sv)
AT (1) ATE227124T1 (sv)
AU (1) AU710339B2 (sv)
CA (1) CA2200761C (sv)
CZ (1) CZ293873B6 (sv)
DE (1) DE69528773T2 (sv)
DK (1) DK0784476T3 (sv)
ES (1) ES2184808T3 (sv)
FI (1) FI116659B (sv)
HU (1) HU225493B1 (sv)
IS (1) IS1956B (sv)
NO (1) NO314486B1 (sv)
NZ (1) NZ293642A (sv)
PL (1) PL181802B1 (sv)
PT (1) PT784476E (sv)
SK (1) SK281932B6 (sv)
WO (1) WO1996011009A1 (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001157A1 (en) * 1996-07-05 1998-01-15 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
DK1571970T3 (da) 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
CN104095851A (zh) * 2003-05-15 2014-10-15 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2007100668A2 (en) 2006-02-24 2007-09-07 Shire Llc Antidepressant prodrugs
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc METHODS AND THERAPEUTIC COMPOUNDS
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
PL2766029T3 (pl) 2011-10-10 2020-08-24 Ampio Pharmaceuticals, Inc. Leczenie choroby zwyrodnieniowej stawów
KR20140075772A (ko) 2011-10-10 2014-06-19 앰피오 파마슈티컬스 인코퍼레이티드 면역 내성을 증가시킨 이식 의료 장비, 및 그의 제조 및 이식 방법
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
MX2015010937A (es) 2013-03-15 2015-10-29 Ampio Pharmaceuticals Inc Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
CA3041358A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
CA3061340A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
DE69528773T2 (de) 2003-09-04
EP0784476B1 (en) 2002-11-06
FI971290A (sv) 1997-06-02
JPH10508583A (ja) 1998-08-25
PL319830A1 (en) 1997-09-01
IS1956B (is) 2004-11-15
DE69528773D1 (de) 2002-12-12
DK0784476T3 (da) 2003-03-17
NZ293642A (en) 1998-10-28
CZ99597A3 (en) 1997-11-12
WO1996011009A1 (en) 1996-04-18
IS4454A (is) 1997-03-26
SK281932B6 (sk) 2001-09-11
HU225493B1 (en) 2007-01-29
CA2200761C (en) 2008-02-26
CA2200761A1 (en) 1996-04-18
PL181802B1 (en) 2001-09-28
ES2184808T3 (es) 2003-04-16
NO314486B1 (no) 2003-03-31
CZ293873B6 (cs) 2004-08-18
AU3612695A (en) 1996-05-02
US6096737A (en) 2000-08-01
AU710339B2 (en) 1999-09-16
SK43897A3 (en) 1998-08-05
PT784476E (pt) 2003-03-31
NO971539L (no) 1997-04-04
HUT77380A (hu) 1998-04-28
FI971290A0 (sv) 1997-03-26
ATE227124T1 (de) 2002-11-15
EP0784476A1 (en) 1997-07-23
NO971539D0 (no) 1997-04-04
US6569850B1 (en) 2003-05-27

Similar Documents

Publication Publication Date Title
FI116659B (sv) Användning av föreningar vid framställning av läkemedel för behandling av multipel skleros (MS) och andra myelinminskningstillstånd
US10786469B2 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273133B2 (en) Bupropion as a modulator of drug activity
Glassman et al. Potentiation of a monoamine oxidase inhibitor by tryptophan
CN112437659B (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
Mavissakalian et al. Imipramine dose-response relationship in panic disorder with agoraphobia: Preliminary findings
CN115697314A (zh) 安非他酮和右美沙芬组合用于治疗神经病症的用途
JP2008201799A (ja) コカイン依存症治療用薬剤
JP2004519461A5 (sv)
JP2004519461A (ja) アルコール依存症治療用薬剤の製造時におけるフルマゼニルの使用
US10925879B2 (en) Methods of treating developmental disorders and/or seizure disorders with etifoxine
JP2003522112A5 (sv)
KR20230131927A (ko) 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합
AU2022374097A1 (en) 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
EP3585380A1 (en) Methods of treating seizure disorders
Qureshi et al. Pharmacotherapies of addiction
Dinan Lithium potentiation and treatment of refractory depression
SHERMAN Injectable Naltrexone Shows Improved Efficacy
MXPA06007770A (en) Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
AU2006200922A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AMARIN NEUROSCIENCE LIMITED

Free format text: AMARIN NEUROSCIENCE LIMITED

FG Patent granted

Ref document number: 116659

Country of ref document: FI